Y-Intercept (HK)
OCUL icon

Y-Intercept (HK)’s Ocular Therapeutix OCUL Stock Holding History

Y-Intercept (HK)’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-14,007
Closed -$138K – 1955
2026
Q2 		$138K Sell
14,007
-40,696
-74% -$369K ﹤0.01% 1593
2026
Q1 		$463K Sell
54,703
-340,632
-86% -$3.25M 0.01% 1277
2025
Q4 		$4.8M Buy
+395,335
New +$4.8M 0.11% 241
2025
Q3 		– Sell
-36,815
Closed -$342K – 1901
2025
Q2 		$342K Buy
+36,815
New +$288K 0.01% 1324
2024
Q2 		– Sell
-20,523
Closed -$187K – 1769
2024
Q1 		$187K Buy
+20,523
New +$146K 0.01% 1174

Other funds holding OCUL

Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
E. Ohman J:or Asset Management
E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return
Courier Capital
Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Financial Management Network
Financial Management Network Mission Viejo, California $695M AUM 13.16% 1-Year Est. Return
Relyea Zuckerberg Hanson
Relyea Zuckerberg Hanson Stamford, Connecticut $1.21B AUM 20.62% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Beacon Investment Advisory Services
Beacon Investment Advisory Services Morristown, New Jersey $2.66B AUM 29.77% 1-Year Est. Return
Trust Company of Vermont
Trust Company of Vermont Brattleboro, Vermont $2.8B AUM

Y-Intercept (HK)'s OCUL Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Ocular Therapeutix (OCUL) in Q3 2026, closing a stake of 14,007 shares — an estimated $138K sold.

Y-Intercept (HK) first reported a position in OCUL in Q1 2024 and held it in 5 quarters. The position peaked at $4.8M in Q4 2025. 27 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Ocular Therapeutix position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 14,007 Ocular Therapeutix shares in Q3 2026, an estimated $138K.
  • Y-Intercept (HK) first reported a position in Ocular Therapeutix in Q1 2024 and held it in 5 quarters.
  • Y-Intercept (HK)'s Ocular Therapeutix position peaked at $4.8M in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.